Effect of Natural and ARV-Induced Viral Suppression and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Patients with HIV-1 Subtype B Infection

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wendel, Sarah K ^a   Mullis, Caroline E ^b   Eshleman, Susan H ^b   Blankson, Joel N ^b   Moore, Richard D ^b   Keruly, Jeanne C ^b   Brookmeyer, Ron ^c   Quinn, Thomas C ^a,b   Laeyendecker, Oliver ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; VIRUS RNA;

ADULT; ANALYTICAL EQUIPMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BED CAPTURE ENZYME IMMUNOASSAY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; TREATMENT DURATION; UNITED STATES; VIRAL BREAKTHROUGH; VIRAL PHENOMENA AND FUNCTIONS; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIBODY AFFINITY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; TIME FACTORS;

EID: 84874274559     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055525     Document Type: Article

References (30)

1. Brookmeyer R, (2010) Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev 32: 26-37.
2. Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, et al. (2002) Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol 156: 641-653.
3. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280: 42-48.
4. Hallett TB, Ghys P, Barnighausen T, Yan P, Garnett GP, (2009) Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One 4: e5720.
5. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, et al. (2011) Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses 27.
6. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR, (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
7. Kahle E, Kasuba A, Baeten J, Delany S, Donnell D, et al. (2012) Unreported antiretroviral use by HIV-1 infected members of HIV-1 serodiscordant couples enrolling in an HIV-1 prevention clinical trial; 15-18 April; International Microbicides Conference, Sydney, Australia.
8. Zhang C, Denti P, Walt JS, Ren Y, Smith P, et al. (2012) Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring. Ther Drug Monit. 34: 481-4.
9. Orrell C, Kaplan R, Wood R, Bekker LG, (2011) Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. AIDS Res Treat 2011: 469127.
10. Incidence Assay Critical Path Working Group (2011) More and Better Information to Tackle HIV Epidemics: Towards Improved HIV Incidence Assays. PLoS Med 8: e1001045.
11. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, et al. (2010) Estimating HIV incidence in populations using tests for recent infection: issues, challenges and the way forward. Journal of HIV/AIDS Surveillance and Epidemiology 2: 1-14.
12. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, et al. (2010) Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24: 2763-2771.
13. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18: 295-307.
14. Murphy G, Parry JV, (2008) Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 13: pii18966.
15. Moore RD, (1998) Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr 17Suppl 1: S38-41.
16. Carr JK, Osinusi A, Flynn CP, Gilliam BL, Maheshwari V, et al. (2010) Two independent epidemics of HIV in Maryland. J Acquir Immune Defic Syndr 54: 297-303.
17. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, et al. (2006) Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770.
18. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, et al. (2007) Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81: 2508-2518.
19. Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN, (2009) Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol 83: 88-97.
20. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS, (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623-2628.
21. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K, et al. (2010) Antibody Avidity-based Assay for Identifying Recent HIV-1 Infections Based on Genetic Systems TM 1/ 2 plus O EIA. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
22. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, et al. (2008) The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr 48: 211-215.
23. Taha TE, James MM, Hoover DR, Sun J, Laeyendecker O, et al. (2011) Association of recent HIV infection and in-utero HIV-1 transmission. AIDS 25: 1357-1364.
24. Welte A, McWalter TA, Laeyendecker O, Hallett TB (2010) Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill 15.
25. Laeyendecker O, Oliver A, Astemborski J, Owen M, Kirk G, et al. (2010) Improved Precision of Cross-sectional HIV Incidence Testing Using a Multi-assay Algorithm that Includes BED and an Avidity Assay with Modified Assay Cut-offs. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
26. Truong HM, Kellogg T, Louie B, Klausner J, Dilley J, et al. (2009) Recent HIV-1 infection detection: comparison of incidence estimates derived by laboratory assays and repeat testing data. J Acquir Immune Defic Syndr 51: 502-505.
27. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, et al. (2010) Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24: 2535-2539.
28. Kassutto S, Johnston MN, Rosenberg ES, (2005) Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 40: 868-873.
29. Hayashida T, Gatanaga H, Tanuma J, Oka S, (2008) Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24: 495-498.
30. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, et al. (2010) Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 53: 496-499.